Status:
COMPLETED
Mobilization by Plerixafor of Haematopoietic Stem Cells in Children
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Children Cancer, Solid Tumor
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE2
Brief Summary
This is a prospective Phase II, monocentre study.
Detailed Description
The extensive chemotherapy followed of hematopoietic stem cells reinjection (HSC) is one therapeutic option which the profit is well demonstrated in the treatment of children's solid tumors. It's one ...
Eligibility Criteria
Inclusion
- 0 to 18 years old
- Solid malign tumor
- Lansky score ≥ 70%
- Indication of hematopoietic stem cell taking by cytapheresis for extensive chemotherapy followed by one or several reinjections of hematopoietic stem cells
Exclusion
- Administration of hematopoietic growth factors in 8 days preceding the injection of Plerixafor.
- Contraindication in the cytapheresis or in the extensive chemotherapy.
- Clinical or biological state dissuading the realization of the cytapheresis
- Chemotherapy in 15 days preceding the injection of plerixafor or neutrophils \< 1500/mm3
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01225419
Start Date
September 1 2010
End Date
May 1 2011
Last Update
July 8 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003